Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have earned an average rating of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $28.3344.

Several brokerages recently issued reports on BCAX. HC Wainwright reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. BTIG Research restated a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Wells Fargo & Company increased their price objective on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. Citizens Jmp began coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They issued a “market perform” rating and a $31.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th.

Bicara Therapeutics Trading Up 4.8%

Shares of BCAX stock opened at $17.59 on Tuesday. Bicara Therapeutics has a 12-month low of $7.80 and a 12-month high of $19.71. The business’s fifty day simple moving average is $16.38 and its 200-day simple moving average is $15.62. The company has a market cap of $963.62 million, a PE ratio of -7.85 and a beta of -0.79.

Insiders Place Their Bets

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 3,828 shares of the stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $18.10, for a total transaction of $69,286.80. Following the sale, the chief operating officer directly owned 210,164 shares of the company’s stock, valued at approximately $3,803,968.40. This trade represents a 1.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Ivan Hyep sold 1,882 shares of Bicara Therapeutics stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $18.15, for a total value of $34,158.30. Following the transaction, the chief financial officer owned 145,355 shares of the company’s stock, valued at $2,638,193.25. The trade was a 1.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 18,359 shares of company stock worth $339,630 in the last quarter. Company insiders own 15.50% of the company’s stock.

Institutional Trading of Bicara Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC purchased a new position in Bicara Therapeutics during the first quarter valued at approximately $248,000. Woodline Partners LP boosted its position in Bicara Therapeutics by 26.5% in the 1st quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after purchasing an additional 72,998 shares in the last quarter. Nan Fung Trinity HK Ltd. acquired a new stake in shares of Bicara Therapeutics during the 2nd quarter worth approximately $3,185,000. Geode Capital Management LLC grew its stake in shares of Bicara Therapeutics by 36.8% during the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after purchasing an additional 180,833 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Bicara Therapeutics by 119.6% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company’s stock valued at $75,000 after purchasing an additional 4,417 shares in the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.